endovascular.es

Título: UPDATED: Bard, Medtronic get additional CMS reimbursement for their drug-coated balloons
Fecha: 10-06-2015
C.R. Bard ($BCR) announced that the federal Centers for Medicare & Medicaid Services further improved reimbursement for its recently launched Lutonix drug-coated balloon for peripheral artery disease in the femoropopliteal arteries (located near the knee).
'After further review, CMS determined that costs associated with DCBs were not included in existing reimbursement for percutaneous transluminal angioplasty, stenting, or atherectomy procedures. Therefore, CMS is removing the device offset charge from the calculation and will reimburse the full cost of DCBs in these procedures. This reimbursement determination is retroactive to April 1, 2015,' the company said in a release.
The change will benefit Medtronic's competing In.Pact Admiral drug-coated balloon as well, the company told FierceMedicalDevices in an email.
Fuente: endovascular.es

endovasculares.es